Upstream Bio (UPB) Net Income towards Common Stockholders (2023 - 2025)
Historic Net Income towards Common Stockholders for Upstream Bio (UPB) over the last 3 years, with Q3 2025 value amounting to -$33.7 million.
- Upstream Bio's Net Income towards Common Stockholders fell 6045.26% to -$33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$122.8 million, marking a year-over-year decrease of 7642.73%. This contributed to the annual value of -$76.4 million for FY2024, which is 9969.94% down from last year.
- Per Upstream Bio's latest filing, its Net Income towards Common Stockholders stood at -$33.7 million for Q3 2025, which was down 6045.26% from -$40.0 million recorded in Q2 2025.
- Upstream Bio's 5-year Net Income towards Common Stockholders high stood at -$6.3 million for Q3 2023, and its period low was -$40.0 million during Q2 2025.
- Moreover, its 3-year median value for Net Income towards Common Stockholders was -$21.0 million (2024), whereas its average is -$22.1 million.
- Within the past 5 years, the most significant YoY rise in Upstream Bio's Net Income towards Common Stockholders was 4542.18% (2024), while the steepest drop was 23636.65% (2024).
- Over the past 3 years, Upstream Bio's Net Income towards Common Stockholders (Quarter) stood at -$15.0 million in 2023, then tumbled by 45.42% to -$21.8 million in 2024, then crashed by 54.88% to -$33.7 million in 2025.
- Its last three reported values are -$33.7 million in Q3 2025, -$40.0 million for Q2 2025, and -$27.3 million during Q1 2025.